- Advanced hepatocellular carcinoma (HCC) is commonly treated with sorafenib
- Subset of CD8+ cells are biomarker linked with survival benefit, team shows
- Evidence could lead to more individualized treatments for liver cancer patient
Newswise — BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized treatment options and better overall outcomes for patients diagnosed with the disease.
The 4-year study, led by Department of Immunology scientist Yasmin Thanavala, PhD, was published online this week in JCI Insight, a peer-reviewed journal published by the American Society for Clinical Investigation, and also to be highlighted in the journal’s JCI This Month digest for September 2019.
Hepatocellular carcinoma (HCC), which can arise from liver cirrhosis, is the most common form of liver cancer. The mainstay oral chemotherapy treatment for patients with advanced HCC is sorafenib — but side effects from this drug may cause many patients to miss doses or discontinue treatment.
The researchers, who included Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park, collected blood samples from 30 patients both before treatment and at two timepoints during treatment with sorafenib. They observed elevated levels of a subset of CD8+ cytotoxic T-cells (CD8+ Ki67+ T cells producing IFNg) producing interferon type II, an important immune protein that destroys tumor cells and significantly reduces risk of death over time. Similarly, CD8+ cells showed an increase in granzyme B, an important enzyme that helps drive cell death.
Additional findings showed that patients with a high ratio of CD4+ T-effector/T-regulatory cells prior to treatment showed significant improvement in both progression-free and overall survival. Decreased numbers of two important immune checkpoint proteins expressed on T-cells — PD-1 and CTLA-1 — suggests that a combination treatment of sorafenib with checkpoint inhibitors such as nivolumab and pembrolizumab could produce positive results in the future.
“Studying biomarkers that correlate with progression-free or overall survival can help reduce exposure to therapies that have an impact on a patient’s quality of life and survival,” says Dr. Thanavala, who led this research. “Utilizing this information, our evidence supports the rationale that patients could benefit from a regimen of sorafenib and immunotherapy, which could help with antitumor immunity and improve the magnitude and strength of antitumor responses.”
The study, “Augmentation of IFN-y+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy,” is available at insight.jci.org. This work was supported by the National Cancer Institute, or NCI (grant P30CA016056), the National Comprehensive Cancer Network® (NCCN®) Oncology Research Program from general research support provided by Bayer U.S LLC (NCCNSORA0002), and by donations to Roswell Park.
This release is also available on the Roswell Park website: https://www.roswellpark.org/media/news/roswell-park-researchers-identify-immune-biomarker-response-patients-advanced-liver
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or [email protected].